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Abstract
I-131 metaiodobenzylguanidine (MIBG) is a noradrenaline analogue and acts as an 
adrenergic neuron blocker. It is commonly used in the radionuclide treatment of neu-
roectodermal-derived tumors (Stage III–IV neuroblastoma, inoperable pheochromocy-
toma, paraganglioma and carcinoid tumor, metastatic or recurrent medullary thyroid 
cancer). These are rare tumors and clinical data about therapeutic options accumulate 
slowly. I-131 MIBG has a well-known role in the salvage therapy of these tumors; how-
ever, recent data suggest that it may also be beneficial to use as the first-line method. 
Here, we define characteristics of the radiopharmaceutical, mention cautions during 
administration and discuss clinical applications of I-131 MIBG therapy of the neuroec-
todermal tumors.
Keywords: iodobenzylguanidine, neuroectodermal tumors, therapeutics, neoplasms, 
radiation
1. Introduction
Metaiodobenzylguanidine (MIBG, Iobenguane) is an aralkylguanidine analogue, composed 
of bretylium and guanethidine (an adrenergic neuron blocker). It acts as a noradrenaline 
analogue and is taken up by adrenergic sympathetically innervated tissues. Neural crest 
originated tumors, which are derived from sympathetic nervous system, are therefore suit-
able for scintigraphic imaging and targeted therapy with radioiodine-labeled MIBG. I-131-
labeled MIBG is the compound used for therapy in neuroectodermal tumors. These tumors 
have a very low incidence, and thus clinical experience in therapy with I-131 MIBG is lim-
ited to specific reference centers. This chapter aims to give information about the physical 
characteristics of I-131 MIBG, uptake mechanisms of the radiocompound in the tumoral 
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tissue, indications and contraindications for I-131 MIBG therapy, specifications for the facil-
ity where the therapy will be performed, patient preparation and administration of I-131 
MIBG, follow-up and precautions on possible side effects and make an overview on the 
clinical studies about I-131 MIBG therapy.
2. Radiopharmaceutical
I-131 MIBG is a “theranostic,” the term that stands for the agents used for both diagnostic 
and therapeutic approach [1]. Physical properties of I-131 bring in this advantage. I-131 has a 
gamma ray at 364 keV and a mean beta emission of 606 keV. Beta particular emission causes 
cell death, and gamma rays are used for scintigraphic imaging. A half-life of 8.02 days pro-
vides enough time for labeling and shipping [2].
Metaiodobenzylguanidine (MIBG) is a synthetic analogue of norepinephrine and an aralkyl-
guanidine, a combination of benzyl group of bretylium and guanidine group of guanethidine 
[3]. The reason why MIBG is the preferred pharmaceutical among other aralkylguanidines is 
that it shows the lowest liver uptake, the best in vivo stability, and thus, lowest amount of free 
radioiodine is trapped by thyroid tissue. In a study by Wieland et al., 100 μCi I-125-labeled 
iodobenzylguanidine isomers (para, ortho and meta) were intravenously administered to 41 
mongrel dogs separately. Following injections, tissue distribution of each isomer in a given 
time was detected by obtaining samples from 18 different tissues. They found out that meta 
and para isomers were taken up by adrenal medulla starting from 2 h of injection and lasted 
till 8 days. Despite adrenal medulla is surrounded by liver, an organ with metabolic activity 
and adrenergic innervation, even on the measurements, performed on 5 days of injection, 
the ratio of adrenal medulla counts/liver counts was calculated as high as 1000. In addition 
to adrenal medulla, high amount of radiopharmaceutical uptake was detected in thyroid. 
However, detailed analysis of thyroid tissue measurements revealed that meta-isomer was 
more resistant to in vivo deiodination [4].
I-131 MIBG is rapidly cleared from bloodstream following intravenous administration and 
taken up by adrenergically innervated tissues like adrenal medulla, heart and salivary glands. 
In the first hour, heart and lungs are major apparent organs. Maximal uptake in the tumoral 
tissue occurs 24–96 h later. The major route of elimination of the radiopharmaceutical is glo-
merular filtration. In subject with normal renal function, 50% of the administered activity was 
shown to be excreted unchanged via urine in 24 h and 90% is eliminated by the kidneys in 
4 days. A very small amount of I-131 MIBG is metabolized in vivo (<10%). End products are 
m-iodohippuric acid, m-iodobenzoic acid, 4-hydroxy-3-iodobenzylguanidine and free radio-
iodine [5, 6].
Norepinephrine (NE) is synthesized by dopamine-hydroxylase from dopamine (DA) in pre-
synaptic neurons of adrenal medulla, carried by the vesicles and secreted to the synaptic 
gap. NE then binds to pre- and postsynaptic adrenergic receptors in the synaptic gap. NE 
is reuptaken by the pre- and postsynaptic cells through NE transporters (NETs) and stored 
in the vesicles. This reuptake process is called “specific neuronal uptake 1” and is Na and 
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energy (ATP) dependant. Ligand affinity is high, whereas saturability is low. It is sensitive to 
heat and ouabaine, Na+/K+/ATP’ase inhibitor. MIBG, the Ne analogue, acts similar to NE. As 
the molecular structure remains unchanged, I-131-labeled MIBG is also taken up by the NET 
expressing cells (mainly derived from the neural crest), using NETs. However, this specific 
mechanism of uptake is not the only uptake mechanism of I-131 MIBG uptake in cellular 
level. The second mechanism is nonspecific passive diffusion, which takes place in all cell 
types. Specific neuronal uptake is 50 times more effective than passive diffusion [4, 7, 8]. After 
internalized in the cell, I-131 MIBG is taken up by vesicular monoamine transporters (VMAT 
1 and 2) and stored in neurosecretory granules [9].
3. Indications
Although any tumor capable of I-131 uptake on pretherapy I-131 MIBG scan may have a 
chance to be treated with I-131 MIBG, I-131 MIBG has a well-established place only in therapy 
regimen of some common neuroendocrine tumors: Stage III–IV neuroblastoma (NB), inoper-
able pheochromocytoma, paraganglioma and carcinoid tumor, metastatic or recurrent med-
ullary thyroid cancer [10]. To decide whether a neuroendocrine tumor patient is eligible to 
I-131 MIBG therapy, I-131 MIBG avidity should be concerned first. This decision can be made 
either visually (lesions detectable above background activity on I-123 or I-131 MIBG scan) or 
semiquantitatively (like target/background >2, or >1% of the injected activity taken up by the 
tumor) [11–16].
4. Contraindications
Absolute contraindications for I-131 MIBG therapy are given as pregnancy and breast feed-
ing. If life expectancy is less than 3 months, therapy is not recommended except for those 
given for pain palliation. Renal insufficiency is also an undesirable condition for I-131MIBG 
therapy. Relative contraindications include inconvenient isolation conditions, urinary incon-
tinence, progressive deterioration in renal functions (GFR < 30 ml/min) and myelotoxicity 
(WBC < 3.0 × 109/l, PLT < 100 × 109/l). Patients susceptible to toxicities should be followed up 
closely and activity reduction should be concerned [10].
5. Protocol
5.1. Patient preparation
5.1.1. Eligibility for I-131 MIBG therapy
Patients should be evaluated with I-131 or I-123 MIBG scan before therapy to make sure that 
the tumoral lesions are I-131 MIBG avid [17].
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5.1.2. Thyroid blockade
Unbound or in vivo radiolyzed free radioiodine is taken up by the thyroid and may cause 
destruction. Thyroidal uptake should be inhibited by oral stable iodine. Oral iodine (16–
130 mg/day) or potassium perchlorate capsules (100–400 m/day) can be used, although iodine 
capsules are more preferred in pediatric patients because of its better taste. Lugol solution is 
a simpler alternative, administered 1 drop/kg/day with a maximum of 40 (20 drops twice a 
day). The treatment should begin 48–24 h before I-131 MIBG administration and continued 
for 10–15 days after therapy [10].
5.1.3. Drug interactions
Various drugs interfere with I-131 MIBG uptake in the target tissue. Drug groups and recom-
mended withdrawal times are presented in Table 1. They may inhibit Na-dependent uptake 
to cell, intracellular vesicular uptake, depletion of I-131 MIBG from the granules, Ca-mediated 
uptake and some other unproven pathways [10].
Neuroendocrine tumors, especially PHEO and paragangliomas (PGLs), present with hyper-
tension and tachycardia due to secreted catecholamines. Management includes alpha and beta 
blockers. Discontinuation of these drugs is needed before I-131 MIBG therapy. This causes 
Group Recommended withdrawal time
Antiarrhythmics (amiodaron) Not practical
Combined alpha-beta blockers (labetolol) 72 h
Adrenergic neuron blockers 48 h
Alpha blockers 15 days
Calcium channel blockers 24–48 h
Inotropic sympathomimetics 24 h
Vasoconstrictor sympathomimetics 24 h
B2 stimulants 24 h
Other adrenoreceptor stimulants (Orciprenaline) 24 h
Systemic and nasal decongestants, cough and cold preparations 24–48 h
Sympathomimetics for glaucoma 48 h
Antipsychotics 24 h–15 days
Sedatizing antihistaminics 24 h
Opioid analgesic drugs 24 h
Tricyclic antidepressants 24–48 h
Tricyclic-related antidepressants 48 h–3 days
CNS stimulants 24 h–5 days
Table 1. Drug groups which may interfere with I-131 MIBG uptake and recommended withdrawal time.
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an interruption in symptomatic management. Alpha blocker phenoxybenzamine and beta 
blocker atenolole do not interfere with I-131 MIBG uptake. Among calcium channel blockers, 
nifedipine is a safe option, as interference has not been reported [18].
5.2. Dose administration
The radiopharmaceutical administration can be performed either in or outpatient, accord-
ing to the amount of activity administered and local radiation protection rules. If performed 
 in-patient, dose administration should be performed in an approved nuclear medicine facility 
with appropriately shielded rooms, radiation safety equipment and capability of manage-
ment in case of contamination. Dose administration should be supervised by an authorized 
person, that is, according to the most local commissions, a nuclear medicine specialist [10].
I-131 MIBG is injected intravenously by slow infusion over 1–2 h in a lead shielded infusion 
set [10, 19, 20]. Possible side effects caused by cold MIBG are aimed to be avoided by slow 
infusion. It has been stated that I-131 MIBG at high specific activity has a lower potential to 
cause side effects and thus can be infused in a shorter time period [21].
Vital signs should be closely monitored during and after I-131 MIBG infusion. Short-acting 
alpha and beta blockers should be kept ready during and after infusion in case sympathetic 
discharge symptoms occur. I-131 MIBG infusion can be slowed down or stopped if hyperten-
sion is unstable [10].
5.3. Determination of activity
Empirical fixed dose, fixed activity per body weight or dosimetrically estimated doses can 
be given. Single administered activities range between 100 and 300 mCi (3.7–11.2 GBq). 
Dosimetric calculation is based on dose-limiting side effect, myelotoxicity. Activities deliver-
ing 2–4 Gy dose to blood are calculated. Much higher doses than fixed doses can be given by 
dosimetric approach [22].
In case of repeat administrations, therapy response and toxicities should be taken in consid-
eration to decide which dose to be given. Dose reduction would be appropriate in case of 
hematologic or renal insufficiency [10]
6. Clinical manifestations
6.1. Neuroblastoma
Neuroblastoma (NB) is the most frequent extracranial tumor of childhood (constituting 
8–10% of the pediatric tumors) and presents with metastatic disease in almost half of the 
cases. Originating from the neural crest, NB can be found anywhere in the sympathetic gan-
glion chain but mostly in the adrenal gland [23]. Because of the fact that neuroblastomas show 
high affinity for I-131 MIBG (>90%), I-131 MIBG therapy is of clinical interest for selective 
internal radiotherapy of NB [10, 24].
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Historically, I-131 MIBG was first tried in refractory or relapsed NB patients. Early Phase I 
dose escalation studies investigated I-131 MIBG as a single agent in the therapy of refractory 
neuroblastoma. Several dose regimens have been tried by different investigators, yielding a 
wide range of complete and partial response (CR and PR): 0–66% [25–35]. Weight-based dose 
arrangement is now well established. 2–6 mCi (74–222 MBq)/kg cause mild hematological 
side effects but does not provide a high antitumor efficacy either. Significant antitumoral 
effects start at doses over >6 mCi(222 MBq)/kg [36]. However, the degree of bone marrow 
depression increases by rising doses, and a new approach was developed combining higher 
effective doses with prior cryopreservation of stem cells and bone marrow transplantation 
following I-131 MIBG therapy. Greater than 12 mCi (444 MBq)/kg is the settled limit for stem 
cell rescue [37]. Doses above 15 mCi (555 MBq)/kg are now used for myeloablation either with 
or without myeloablative chemotherapies [36]. Matthay et al. have published a large trial of 
I-131 MIBG monotherapy in refractory or relapsed NB. The vast majority of the patient group 
received 18 mCi (666 MBq)/kg I-131 MIBG, whereas others were given 12 mCi (444 MBq)/
kg. Overall CR and PR rates were found 36%. However, investigators also revealed that age, 
site of disease involvement, previously received therapies and time between first diagnosis 
and first I-131 MIBG dose are important in prediction of treatment success. Response rates 
were 55 and 40% above and below age 12, respectively. Soft tissue, skeletal and bone marrow 
involvement responded in 50, 45 and 26%, respectively. Event-free survival rate was found 
18%, and 2-year overall survival was 29%. Together with hematologic toxicity, to a lesser 
extent, other side effects such as hepatic, pulmonary and infectious toxicities and febrile neu-
tropenia were also reported in this study [38].
I-131 MIBG monotherapy is also combined with myeloablative chemotherapies to be used 
in higher doses with stem cell rescue. A leading study by Yanik et al. suggested that car-
boplatine-etoposide-melphelan in combination with I-131 MIBG therapy administered in 
12 mCi (444 MBq)/kg doses in 12 patients. Therapy was well tolerated and 5/8 patients with 
metastatic disease showed complete and 2/8 showed partial response [39]. In a larger cohort 
group, 3-year event-free survival and overall survival rates were found 38 and 20% in patients 
who had a PR to induction therapy and 20 and 62% in patients who had a progressive disease 
[40]. It was also reported that I-131 MIBG was not detrimental to hematologic recovery after 
stem cell transplantation [41].
In 2000s, in relapsed or refractory NB patients, tandem doses of I-131 MIBG infusions were 
tried. The best therapy responses were achieved after initial dose administration and response 
rates decreased by repeat infusions. That was also true for patients who have already received 
myeloablative doses of I-131 MIBG (>18 Mci(666 MBq)/kg) [42–44]. Although well tolerated, 
overall clinical response rates in a meta-analysis were reported as 30%, even in tandem infu-
sions [45]. This leads the investigators to seek for other strategies to increase the efficacy of 
I-131 MIBG therapy. NET expression increase would be very beneficial to increase I-131 MIBG 
uptake by the tumor cells. Among the chemotherapeuticals, cisplatin and topotecan are agents 
of choice to augment NET expression. While response rates were ameliorated, side effects 
were not significantly aggravated [46, 47]. In a study of refractory NB patients who received 
200 mCi (7.4 GBq) I-131 MIBG in combination with cisplatin, cyclophosphamide (plus etopo-
side and vincristine or not), an overall response rate of 75% was achieved [46].
Radionuclide Treatments40
Promising results experienced over years with I-131 MIBG therapy have lead to a new 
approach, usage of I-131 MIBG in the front-line as a part of the induction therapy for patients 
who do not have a relapsed or refractory tumor yet. Investigators have found that I-131 MIBG 
avid tumors, which are not exposed to chemo-radiotherapies yet, are more responsive to I-131 
MIBG therapy given at the early steps of the therapy algorithm. In the preoperative period, 
I-131 MIBG therapy performed at diagnosis was reported to lead to a response rate of over 
70%, which is obviously higher than the rates obtained after conventional therapies [48]. 
De Kraker et al. proposed three major arguments: First, if performed before surgery, I-131 
MIBG reduced the volume of the primary and metastatic tumors. Second, overlapping toxic 
situations confronted with chemotherapy in combination therapies are avoided. Finally, 
cross-fire effect achieved at the first-line therapy, the ability of the radiation dose given to a 
tumor cell also causes death of the neighboring cells. The authors published the largest study 
in this field with 44 high-risk patients who received two cycles of I-131 MIBG as an induc-
tion therapy and received a response rate of 73% [49]. Bleeker et al. have also reported that 
together with high success rates, side effects were also lower [50]. Combination of I-131 MIBG 
with chemotherapeuticals did not cause a significant increase in side effects [50, 51].
Pain palliation with I-131 MIBG is another secondary benefit reported commonly in NB [31]. 
Low dose (5 mCi (185 MBq)/kg) I-131 MIBG has also been suggested as an effective means for 
pain palliation in metastatic disease [52].
6.2. Pheochromocytoma and paraganglioma
Paragangliomas (PGL) arise from sympathetic chromaffin tissue (adrenal or extraadrenal) 
and parasympathetic ganglions of the head and neck. Pheochromocytomas (PCC), which 
originate from the adrenal medulla, constitute 80% of all paragangliomas (PG) [53, 54]. Most 
PGLs are benign, while about 10% of PCCs and 10–20% of extraadrenal non-head and neck 
PGLs may undergo malignant degeneration [55]. Malignant disease refers to existence of 
metastatic lesions where neuroendocrine tissue is not expected to exist [56–58]. In malignant 
PCC/PGL, malignant disease has a bad prognosis and together with palliative therapy, I-131 
MIBG has been tried [59, 60].
I-131 MIBG was first tried by Sission et al. on MIBG avid PCC patients. Fractionated doses of 
a total of 373–484 mCi (13.8–17.9 GBq) I-131 MIBG was given to five patients and two patients 
responded partially. Hormone secretion was decreased and tumor volume declined by more 
than 50% in these patients [37, 61]. Many other series with larger number of patients came 
afterwards. However, it is hard to make a final conclusion about the effectiveness of I-131 
MIBG therapy on PCC/PGLs because these studies differed in many ways. First of all, as PCC/
PGLs are relatively rare tumors, study populations were small and heterogenous in many 
studies. Patient selection criteria for I-131 MIBG therapy varied. Some administered I-131 
MIBG therapy only in progressive cases, while in some studies patients with stable disease 
were also included. In stable cases, stability may not be totally attributable to the effectiveness 
of I-131 MIBG therapy, as these patients may already have stayed progress free even if no addi-
tional therapies were given. The amount of activity, dose fractionation, time elapsed between 
two therapy sessions, tumor response and hormonal response evaluation criteria were all set 
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differently in these cohorts. Moreover, PCC and PGLs may respond differently to I-131 MIBG 
therapy, and separate analysis of them could give more accurate and realistic results.
In the literature, generally low (64–200 mCi) (2.368–7.4 GBq), intermediate (200–500 mCi) (7.4–
18.5 MBq) and high (1.2–1.8 mCi) (444–666 GBq) doses of I-131 MIBG with stem cell support have 
been tried. Low and intermediate doses were chosen in order to be able to give repeat doses and 
thus decrease toxicities. Tandem doses resulted in cumulative doses as high as 2.3 Ci (85.1 MBq), 
but usually in a range of 500–1000 mCi (18.5–37 MBq). A review analyzing the results of repeat 
low dose I-131 MIBG, CR, PR, SD and PD rates were found 4, 26, 50 and 13%, respectively. 
Objective hormonal response was obtained completely in 13% and partially in 32%. Symptomatic 
relief due to hormonal excess was maintained in 76% of the patients [62]. Comparison of three 
methodologies was reported in 33 patients. Median survival was 4.7 years for patients respond-
ing to I-131 MIBG therapy and 1.7 years for nonresponders. Patients who received high doses 
(>500 mCi) (>18.5 MBq) had a higher survival rate than the low dose group (3.8 versus 2.6 years) 
[63]. A recent meta-analysis by Hulsteijn et al. aimed to present effectiveness of I-131 MIBG ther-
apy in malignant PCC/PGL. If effects on tumor volume are considered, pooled proportions of 
CR, PR and SD were found to be 0.03, 0.27 and 0.52, respectively. Hormonal response rates were 
0.11, 0.4 and 0.21, respectively. Five-year survival rates ranged between 45 and 64% and PFSs were 
23.1–28.5 months. A separate analysis revealed better hormonal response in PGL than PCC [64].
6.3. Others
The use of I-131 MIBG in carcinoid tumors and medullary thyroid carcinoma has been 
reported in relapse or refractory cases. Certain eligibility criterion is of course I-131 MIBG 
avidity proven by I-123 MIBG scan. I-131 MIBG therapy in these patients is rather palliative 
and aims to increase quality of life. Medullary thyroid carcinoma is rare and only about 34% 
of medullary thyroid cancer patients have an I-131 MIBG avidity; thus, the experience in 
this field is quite limited [24, 65–67]. In a study by Safford et al., a relatively wider group of 
patients with metastatic carcinoid tumor were given 77–1076 mCi (2.849–39.812 GBq) (mean 
400 mCi) (mean 14.8 GBq) I-131 MIBG in 1–3 fractions. Symptomatic relief was gained in 
about half of the patients (49%). However, only 15% of them showed tumor volume decrease, 
and no significant effect on survival was reported [68].
7. Toxicity
Early side effects of I-131 MIBG therapy occur in the first hours or days of treatment. Nausea 
and vomiting are common side effects caused by acute radiation gastritis. Antiemetics are rou-
tinely recommended before the infusion starts. Its incidence has been reported between 4 
 and 40% [20, 69–73]. During I-131 MIBG infusion, catecholamine discharge may cause hyper-
tension and tachycardia in 20% of the patients [11]. Although slow infusion and high specific 
activity preparations may decrease probability, alpha and beta blockers should be prepared to 
be used in case of emergency. Acute parotitis can be caused by I-131 MIBG uptake in the salivary 
glands. Anti-inflammatory agents may help symptomatic relief. Chronic xerostomia has not 
been reported yet [74].
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The most important subacute toxicity is hematotoxicity. Bone marrow is the dose-limiting 
organ for I-131 MIBG therapy. Because I-131 MIBG binds to platelets, thrombocytopenia is 
usually more apparent than leucopenia. Hematotoxicity is dose dependent. Doses above 
12 mCi(444 MBq)/kg have been shown to cause severe bone marrow toxicity, and in cases 
of doses exceeding 15 mCi(555 MBq)/kg or repeat doses, stem cell support is required [24, 
75, 76].
Late complications of I-131 MIBG include hypothyroidism and secondary malignancies. 
Hypothyroidism is a result of destruction caused by free radioiodine existing in the product 
or released after I-131 is metabolized. It is seen months or years after therapy in about 7–12% 
of the patients [77–81]. This is why thyroid blocking is essential during therapy.
Secondary malignancies such as myelodisplastic syndrome (MDS) and acute myelogenous 
leukemia (AML) have been reported in about 2–4% of patients [82–84]. As these patients 
are treated with chemo-radiotherapies in combination with I-131 MIBG, the contribution of 
I-131 MIBG alone to secondary malignancy development is a matter of debate. Alkylator-
based chemotherapeuticals and external radiotherapy are also responsible for mutagenic 
effects [85].
Other side effects of I-131 MIBG such as pulmonary, cardiac and neurologic complications are 
rare. However, as liver shows high I-131 MIBG uptake, hepatotoxicity may become clinically 
evident at high doses. However, this effect is usually transient and aggravated by combina-
tion chemo-radiotherapies [81, 86]. Hypogonadism has been reported in higher frequencies 
with higher I-131 MIBG doses [11, 73, 87].
8. Noncarrier-added I-131 MIBG: an attempt to increase therapy efficiency
I-131 MIBG is synthesized from I-127 MIBG (cold MIBG) by substituting stable iodine by 
radioiodine [88]. The end product contains I-131 MIBG/I-127 MIBG ratio of 1:2000 [89]. This 
impurity causes a competition of I-131 and I-127 MIBG for NET and heterogenous tumoral 
uptake of I-131 MIBG, leaving a considerable amount of tumor cells nonirradiated. Excess 
MIBG, by the way, can cause symptoms due to sympathetic discharge. Non-carrier added 
I-131 MIBG was developed both to increase efficiency and to decrease side effects [90]. 
Noncarrier-added I-131 MIBG will probably be a favorable alternative form after toxicity, and 
dose escalation studies are completed [91].
Author details
Mine Araz* and Derya Çayır
*Address all correspondence to: minesoylu@yahoo.com
Nuclear Medicine Department, Diskapi Yildirim Beyazit Training and Research Hospital, 
Ankara, Turkey
I-131 Metaiodobenzylguanidine Therapy of Neuroectodermal Tumors
http://dx.doi.org/10.5772/intechopen.68573
43
References
[1] McCready VR. Radioiodine—The success story of Nuclear Medicine: 75th anniversary 
of the first use of Iodine-131 in humans. European Journal of Nuclear Medicine and 
Molecular Imaging. 2017;44:179-182
[2] Saha GB. Characteristics of specific radiopharmaceuticals. Fundamentals of Nuclear 
Pharmacy. 4th ed. New York: Springer Verlag; 1998. pp. 112-147
[3] Vallabhajosula S, Nikolopoulou A. Radioiodinated metaiodobenzylguanidine (MIBG): 
Radiochemistry, biology, and pharmacology. Seminars in Nuclear Medicine. 2011;41: 
324-333
[4] Wieland DM, Wu J, Brown LE, et al. Radiolabeled adrenergic neuron-blocking agents: 
Adrenomedullary imaging with [131I]iodobenzylguanidine. Journal of Nuclear Medicine. 
1980;21:349-353
[5] Boersma HH, Wensing JW, Kho TL, de Brauw LM, Liem IH, van Kroonenburgh MJ. 
Transient enhance uptake of 123I-metaiodobenzylguanidine in the contralateral adrenal 
region after resection of an adrenal pheochromocytoma. The New England Journal of 
Medicine. 2000;342:1450-1451
[6] Mangner TJ, Tobes MC, Wieland DM, et al. Metabolism of meta-I-131-iodobenzyl-gua-
nidine in patients with metastatic pheochromocytoma. Journal of Nuclear Medicine. 
1986;27:37-44
[7] Wieland DM, Brown LE, Tobes MC, et al: Imaging the primate adrenal medulla with 
[123I] and [131I] meta-iodobenzylguanidine: Concise communication. Journal of Nuclear 
Medicine. 1981;22:358-364
[8] Wafelman AR, Hoefnagel CA, Maes RA, Beijnen JH. Radioiodinated metaiodobenzyl-
guanidine: A review of its biodistribution and pharmacokinetics, drug interaction, cyto-
toxicity and dosimetry. European Journal of Nuclear Medicine. 1994;21:545-559
[9] Kölby L, Bernhardt P, Levin-Jakobsen AM, Johanson V, Wängberg B, Ahlman H, 
Forssell-Aronsson E, Nilsson O. Uptake of meta-iodobenzylguanidine in neuroen-
docrine tumours is mediated by vesicular monoamine transporters. British Journal of 
Cancer. 2003;89(7):1383-1388
[10] Giammarile F, Chiti A, Lassmann M, Brans B, Flux G. EANM guideline: EANM pro-
cedure guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG) therapy. European 
Journal of Nuclear Medicine and Molecular Imaging. 2008;35:1039-1047
[11] Gonias S, Goldsby R, Matthay KK, et al. Phase II study of highdose [131I] metaiodoben-
zylguanidine therapy for patients with metastatic pheochromocytoma and paragangli-
oma. Journal of Clinical Oncology. 2009;27:4162-4168
Radionuclide Treatments44
[12] Pasieka JL, McEwan AJB, Rorstad O. The palliative role of I-131-MIBG and In-111-
octreotide therapy in patients with metastatic progressive neuroendocrine neoplasms. 
Surgery. 2004;136:1218-1226
[13] Nguyen C, Faraggi M, Giraudet AL, et al. Long-term efficacy of radionuclide therapy 
in patients with disseminated neuroendocrine tumors uncontrolled by conventional 
therapy. Journal of Nuclear Medicine. 2004;45:1660-1668
[14] Shapiro B, Sisson JC, Lloyd R, et al. Malignant pheochromocytoma—Clinical, biochemi-
cal and scintigraphic characterization. Clinical Endocrinology. 1984;20:189-203
[15] Taal BG, Hoefnagel CA, Valdes-Olmos RA, et al. Palliative effect of metaiodobenzylgua-
nidine in metastatic carcinoid tumors. Journal of Clinical Oncology. 1996;14:1829-1838
[16] Pathirana AA, Vinjamuri S, Byrne C, et al. I-131-MIBG radionuclide therapy is safe and 
cost-effective in the control of symptoms of the carcinoid syndrome. European Journal 
of Surgical Oncology. 2001;27:404-408
[17] Vaidyanathan G. Meta-iodobenzylguanidine and analogues: Chemistry and biology. 
The Quarterly Journal of Nuclear Medicine and Molecular Imaging. 2008;52:351-368
[18] Blake GM, Lewington VJ, Fleming JS, et al. Modification by nifedipine of I-131-meta-
iodobenzylguanidine kinetics in malignant pheochromocytoma. European Journal of 
Nuclear Medicine. 1988;14:345-348
[19] Schlumberger M, Gicquel C, Lumbroso J, et al. Malignant pheochromocytoma-Clinical, 
biological, histologic and therapeutic data in a series of 20 patients with distant metasta-
ses. Journal of Endocrinological Investigation. 1992;15:631-642
[20] Shapiro B, Sisson JC, Wieland DM, et al. Radiopharmaceutical therapy of malignant 
pheochromocytoma with I-131 metaiodobenzylguanidine: Results from ten years of 
experience. Journal of Nuclear Biology and Medicine. 1991;35:269-276
[21] Coleman RE, Stubbs JB, Barrett JA, et al. Radiation dosimetry, pharmacokinetics, and 
safety of ultratrace (TM) iobenguane I-131 in patients with malignant pheochromocytoma/
paraganglioma or meta-static carcinoid. Cancer Biotherapy and Radiopharmaceuticals. 
2009;24:469-475
[22] Carrasquillo JA, Pandit-Taskar N, Chen CC. I-131 metaiodobenzylguanidine therapy of 
pheochromocytoma and paraganglioma. Seminars in Nuclear Medicine. 2016;46:203-214
[23] Luksch R, Castellani MR, Collini P, De Bernardi B, Conte M, Gambini C, Gandola L, 
Garaventa A, Biasoni D, Podda M, Sementa AR, Gatta G, Tonini GP. Neuroblastoma 
(Peripheral neuroblastic tumours). Critical Reviews in Oncology/Hematology. 2016;107: 
163-181
[24] Sisson JC, Yanik GA. Theranostics: Evolution of the radiopharmaceutical. Seminars in 
Nuclear Medicine. 2012;42:171-184
I-131 Metaiodobenzylguanidine Therapy of Neuroectodermal Tumors
http://dx.doi.org/10.5772/intechopen.68573
45
[25] Hutchinson RJ, Sisson JC, Miser JS, et al. Long-term results of [131I] metaiodobenzylgua-
nidine treatment of refractory advanced neuroblastoma. Journal of Nuclear Biology and 
Medicine. 1991;35:237-240
[26] Hutchinson RJ, Sisson JC, Shapiro B, et al. 131-I metaiodobenzylguanidine treatment in 
patients with refractory advanced neuroblastoma. American Journal of Clinical Oncology. 
1992;15:226-232
[27] Lashford LS, Lewis IJ, Fielding SL, et al. Phase I/II study of iodine 131 metaiodobenzyl-
guanidine in chemoresistant neuroblastoma. A United Kingdom children’s cancer study 
group investigation. Journal of Clinical Oncology. 1992;10:1889-1896
[28] Matthay KK, Huberty JP, Hattner RS, et al. Efficacy and safety of [131I] metaiodoben-
zylguanidine therapy for patients with refractory neuroblastoma. Journal of Nuclear 
Biology and Medicine. 1991;35:244-247
[29] Klingebiel T, Feine U, Treuner J, et al. Treatment of neuroblastoma with [131I] metaiodo-
benzylguanidine: Long-term results in 25 patients. Journal of Nuclear Biology and 
Medicine. 1991;35:216-219
[30] Trancone L, Rufini V, Riccardi R, et al. The use of [131I] metaiodobenzylguanidine in the 
treatment of neuroblastoma after conventional therapy. Journal of Nuclear Biology and 
Medicine. 1991;35:232-236
[31] Kang TI, Brophy P, Hickson M, et al. Targeted radiotherapy with submyeloablative 
doses of 131I MIBG is effective for disease palliation in highly refractory neuroblastoma. 
Journal of Pediatric Hematology/Oncology. 2003;25:769-773
[32] Claudiani F, Garaventa A, Bertolazzi L, et al. [131I] metaiodobenzylguanidine therapy 
in advanced neuroblastoma. Journal of Nuclear Biology and Medicine. 1991;35:224-227
[33] Garaventa A, Bellgamba O, Lo Piccolo MS, et al. 131I-metaiodobenzylguanidine 
(131I-MIBG) therapy for residual neuroblastoma. A mono-institutional experience with 
43 patients. British Journal of Cancer. 1999;81:1378-1384
[34] Hoefnagel CA, Voute PA, De Kraker J, et al. [131I] metaiodobenzylguanidine therapy 
after conventional therapy for neuroblastoma. Journal of Nuclear Biology and Medicine. 
1991;35:202-206
[35] Lumbroso J, Hartmann O, Schlumberger M. Therapeutic use of [131I] metaiodobenzylgua-
nidine in neuroblastoma. A phase II study in 26 patients. Societe Francaised’oncologie 
pediatrique and nuclear medicine co-investigators. Journal of Nuclear Biology and 
Medicine. 1991;35:220-223
[36] Parisi MT, Eslamy H, Park JR, Shulkin BL, Yanik GA. 131I-metaiodobenzylguanidine ther-
anostics in neuroblastoma: Historical perspectives; practical applications. Seminars in 
Nuclear Medicine. 2016;46:184-202
[37] Matthay KK, De Santes K, Hasegawa B, et al. Phase I dose escalation of 131I-metaiodo-
benzylguanidine with autologous bone marrow support in refractory neuroblastoma. 
Journal of Clinical Oncology. 1998;16:229-236
Radionuclide Treatments46
[38] Matthay KK, Yanik G, Messina J, et al. Phase II study on the effect of disease sites, age, 
and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in 
refractory neuroblastoma. Journal of Clinical Oncology. 2007;25:105410-105460
[39] Yanik GA, Levine JE, Matthay KK. Pilot study of iodine-131-metaiodobenzylguanidine 
in combination with myeloablative chemotherapy and autologous stem-cell support for 
the treatment of neuroblastoma, Journal of Clinical Oncology. 2002;15;20(8):2142-2149
[40] Yanik GA, Villablanca J, Maris JM, et al. 131I-metaiodobenzylguanidine with intensive 
chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma. 
A new approaches to neuroblastoma therapy (NANT) phase II study. Biology of Blood 
Marrow Transplant. 2015;21:673-681
[41] Klingebiel T, Bader P, Bares R, et al. Treatment of neuroblastoma stage 4 with 131I-meta-
iodo-benzylguanidine, high dose chemotherapy and immunotherapy. A pilot study. 
European Journal of Cancer. 1998;34:1398-1402
[42] Howard JP, Maris JM, Kersun LS, et al. Tumor response and toxicity with multiple infu-
sions of high dose 131I-MIBG for refractory neuroblastoma. Pediatric Blood Cancer. 
2005;44:232-239
[43] Matthay KK, Quach A, Huberty J, et al. Iodine-131-metaiodobenzylguanidine double 
infusion with autologous stem cell rescue for neuroblastoma. A new approaches to neu-
roblastoma therapy phase 1 study. Journal of Clinical Oncology. 2009;27:1020-1025
[44] Johnson K, McGlynn B, Saggio J, et al. The safety and efficacy of tandem 131I-metaiodoben-
zylguanidine infusions in relapsed/refractory neuroblastoma. Pediatric Blood Cancer. 
2011;57:1124-1129
[45] Wilson JS, Gaines JE, Moroz V, et al. A systematic review of 131I-metaiodobenzylguanidine 
molecular therapy for neuroblastoma. European Journal of Cancer. 2014;50:801-815
[46] Mastrangelo R, Tornesello A, Lasorella A, et al. Optimal use of the 131-I-metaiodobenzyl-
guanidine and cisplatin combination in advanced neuroblastoma. Journal of Neuro-
Oncology. 1997;31:153-158
[47] Meco D, Lasorella A, Riccardi A, et al. Influence of cisplatin and doxorubicin on 125I-meta-
iodobenzylguanidine uptake in human neuroblastoma cell lines. European Journal of 
Cancer. 1999;35:1227-1234
[48] Hoefnagel CA, De Kraker J, Valdes-Olmos RA, et al. 131I-MIBG as a first line treatment in 
high-risk neuroblastoma patients. Nuclear Medicine Communications. 1994;15:712-717
[49] De Kraker J, Hoefnagel KA, Verschuur AC, et al. Iodine-131-metaiodobenxylguanidine as 
initial induction therapy in stage 4 neuroblastoma patients over 1 year of age. European 
Journal of Cancer. 2008;44:551-556
[50] Bleeker G, Schoot RA, Caron HN, et al. Toxicity of upfront 131I-metaiodobenzylguanidine 
(131I-MIBG) therapy in newly diagnosed neuroblastoma patients: A retrospective review. 
European Journal of Nuclear Medicine and Molecular Imaging. 2013;40:1711-1717
I-131 Metaiodobenzylguanidine Therapy of Neuroectodermal Tumors
http://dx.doi.org/10.5772/intechopen.68573
[51] Kraal KC, Tytgat GA, van Eck-Smit BL, et al. Up front treatment of high-risk neuro-
blastoma with a combination of 131I-MIBG and topotecan. Pediatric Blood Cancer. 
2015;62:1886-1891
[52] Weyl Ben-Arush M, Ben Barak A, Bar-Deroma R. Targeted therapy with low doses of 
131I-MIBG is effective for disease palliation in highly refractory neuroblastoma. Israel 
Medicine Association Journal. 2013;15:31-34
[53] De Lellis RA, Lloyd RV, Heitz PU, et al. World Health Organization classification of 
tumours. Pathology and Genetics of Tumours of Endocrine Organs. Lyon: IARC Press; 
2004
[54] Pacak K, Keiser H, Eisenhofer G. Pheochromocytoma. In: De Groot LJ, Jameson JL, edi-
tors. Textbook of Endocrinology. Philadelphia: Elsevier Saunders Inc; 2005. pp. 2501-2534
[55] Chrisoulidou A, Kaltsas G, Ilias I, et al. The diagnosis and management of malignant 
phaeochromocytoma and paraganglioma. Endocrine Related Cancer. 2007;14:569-585
[56] Granger JK, Houn HY. Head and neck paragangliomas: A clinicopathologic study with 
DNA flow cytometric analysis. Southern Medical Journal. 1990;83:1407-1412
[57] Linnoila RI, Keiser HR, Steinberg SM, et al. Histopathology of benign versus malig-
nant sympathoadrenal paragangliomas: Clinicopathologic study of 120 cases including 
unusual histologic features. Human Pathology. 1990;21:1168-1180
[58] Scholz T, Schulz C, Klose S, et al. Diagnostic management of benign and malignant 
pheochromocytoma. Experimental and Clinical Endocrinology & Diabetes. 2007;115: 
155-159
[59] Fitzgerald PA, Goldsby RE, Huberty JP, et al. Malignant pheochromocytomas and para-
gangliomas: A phase II study of therapy with high-dose 131I-metaiodobenzylguanidine 
(131IMIBG). Annals of the New York Academy of Sciences. 2006;1073:465-490
[60] Sisson JC, Shapiro B, Beierwaltes WH, et al. Radiopharmaceutical treatment of malig-
nant pheochromocytoma. Journal of Nuclear Medicine. 1984;25:197-206
[61] Taggart D, Dubois S, Matthay KK. Radiolabeled metaiodobenzylguanidine for imaging 
and therapy of neuroblastoma. Quarterly Journal of Nuclear Medicine and Molecular 
Imaging. 2008;52(4):403-418
[62] Loh KC, Fitzgerald PA, Matthay KK, et al. The treatment of malignant metaiodobenzyl-
guanidine (I-131-MIBG): A comprehensive review of 116 reported patients. Journal of 
Endocrinology Investigation. 1997;20(11):648-658
[63] Safford SD, Coleman E, Gockerman JP, et al. Iodine-131 metaiodobenzylguanidine is 
an effective treatment for malignant pheochromocytoma and paraganglioma. Surgery. 
2003;134:956-962
[64] van Hulsteijn LT, Niemeijer ND, Dekkers OM, Corssmit EP. (131)I-MIBG therapy for 
malignant paraganglioma and phaeochromocytoma: Systematic review and meta-anal-
ysis. Clinical Endocrinology (Oxford). 2014;80:487-501
Radionuclide Treatments48
[65] Hoefnagel CA, Voûte PA, de Kraker J, Marcuse HR, Radionuclide diagnosis and therapy 
of neural crest tumors using iodine-131 metaiodobenzylguanidine. Journal of Nuclear 
Medicine. 1987;28:308-314
[66] Clarke SE, Lazarus CR, Edwards S. Scintigraphy and treatment of medullary carcinoma 
of the thyroid with iodine-131 metaiodobenzylguanidine. Journal of Nuclear Medicine. 
1987;28:1820-1825
[67] Kratochwil C, Giesel FL. Radionuclide therapy of endocrine-related cancer. Radiologe. 
2014;54:1007-1015
[68] Safford SD, Coleman RE, Gockerman JP, et al. Iodine-131 metaiodobenzylguanidine 
treatment for metastatic carcinoid. Results in 98 patients. Cancer. 2004;101:1987-1993
[69] Mukherjee JJ, Kaltsas GA, Islam N, et al. Treatment of metastatic carcinoid tumours, 
phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with 
I-131-meta-iodobenzylguanidine (I-131-MIBG). Clinical Endocrinology. 2001;55:47-60
[70] Gedik GK, Hoefnagel CA, Bais E, et al. 131I-MIBG therapy in metastatic phaeochromo-
cytoma and paraganglioma. European Journal of Nuclear Medicine and Molecular 
Imaging. 2008;35:725-733
[71] Whittle SB, Smith V, Doherty E, Zhao S, McCarty S, Zage PE. Overview and recent 
advances in the treatment of neuroblastoma. Expert Review of Anticancer Therapy. 
2017. DOİ: 10.1080/14737140.2017.1285230. 2017 ;17:369-386
[72] Rose B, Matthay KK, Price D, et al. High-dose I-131-metaiodobenzylguanidine therapy 
for 12 patients with malignant pheochromocytoma. Cancer. 2003;98:239-248
[73] Rutherford MA, Rankin AJ, Yates TM, et al. Management of metastatic phaeochromo-
cytoma and paraganglioma: Use of iodine-131-meta-iodobenzylguanidine therapy in a 
tertiary referral centre. QJM. 2015;108:361-368
[74] Modak S, Pandit-Taskar N, Kushner BH, et al. Transient sialadenitis: A complication of 
131I-metaiodobenzylguanidine therapy. Pediatric Blood Cancer. 2008;50:1271-1273
[75] DuBois SG, Messina J, Maris JM, Huberty J, Glidden DV, Veatch J, Charron M, Hawkins 
R, Matthay KK. Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine 
therapy for advanced neuroblastoma. Journal of Clinical Oncology. 2004;22:2452-2460
[76] Shusterman S, Grant FD, Lorenzen W, et al. Iodine-131-labeled Meta-iodobenzylguanidine 
therapy of children with neuroblastoma: Program planning and initial experience. 
Seminars in Nuclear Medicine. 2011;41:354-363
[77] Picco P, Garaventa A, Claudiani F, et al. Primary hypothyroidism as a consequence of 
131-I-metaiodobenzylguanidine treatment for children with neuroblastoma. Cancer. 
1995;76:1662-1664
[78] Van Santen HM, De Kraker J, van Eck BL, et al. High incidence of thyroid dysfunction 
despite prophylaxis with potassium iodide during 131I-metaiodobenzylguanidine treat-
ment in children with neuroblastoma. Cancer. 2002;94:2081-2089
I-131 Metaiodobenzylguanidine Therapy of Neuroectodermal Tumors
http://dx.doi.org/10.5772/intechopen.68573
49
[79] Van Santen HM, De Kraker J, van Eck BL, et al. Improved radiation protection of the 
thyroid gland with thyroxine, methimazole, and potassium iodide during diagnostic 
and therapeutic use of radiolabeled metaiodobenzylguandine in children with neuro-
blastoma. Cancer. 2003;98:389-396
[80] Van Santen HM, De Kraker J, Vulsma T. Endocrine late effects from multimodality treat-
ment of neuroblastoma. European Journal of Cancer. 2005;41:1767-1774
[81] Quach A, Ji L, Mishra V, et al. Thyroid and hepatic function after high-dose 
131I-metaiodobenzylguanidine (131I-MIBG) therapy for neuroblastoma. Pediatric Blood 
Cancer. 2011;56:191-201
[82] Polishuck AL, DuBois SG, Hass-Kogan D, et al. Response, survival, and toxicity after 
iodine-131-metaiodobenzylguanidine therapy for neuroblastoma in preadolescents, 
adolescents, and adults. Cancer. 2011;117:4286-4293
[83] Garaventa A, Gambini C, Villavecchia G, et al. Second malignancies in children with 
neuroblastoma after combined treatment with 131I-metaiodobenzylguanidine. Cancer. 
2003;97:1332-1338
[84] Weiss B, Vora A, Huberty J, et al. Secondary myelodysplastic syndrome and leukemia 
following 131I-metaiodobenzylguanidine therapy for relapsed neuroblastoma. Journal of 
Pediatric Hematology/Oncology. 2003;25:543-547
[85] Tonakie A, Shulkin BL, Sisson JC, et al. Radiation-induced osteosarcoma and papillary 
thyroid carcinoma of the thyroid. Clinical Nuclear Medicine. 2006;31:5-8
[86] Matthay KK, Tan JC, Villablanca JG, et al. Phase 1 dose escalation of iodine-131-me-
taiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell 
transplantation in refractory neuroblastoma: A new approaches to neuroblastoma ther-
apy consortium study. Journal of Clinical Oncology. 2006;24:500-506
[87] George SL, Falzone N, Chittenden S, Kirk SJ, Lancaster D, Vaidya SJ, Mandeville H, Saran 
F, Pearson AD, Du Y, Meller ST, Denis-Bacelar AM, Flux GD. Individualized 131I-mIBG 
therapy in the management of refractory and relapsed neuroblastoma. Nuclear Medicine 
Communication. 2016;37:466-472
[88] Mangner JT, Wu J-L, Wieland DM. Solid-phase exchange radioiodination of aryl iodides: 
Facilitation by ammonium sulfate. The Journal of Organic Chemistry. 1982;47:1484-1488
[89] Vaidyanathan G, Zalutsky MR. No-carrier-added synthesis of meta-[131I]iodobenzylgua-
nidine. Applied Radiation and Isotopes. 1999;44:621-628
[90] Hunter DH, Zhu X. Polymer-supported radiopharmaceuticals: [131I] MIBG and [123I] 
MIBG. Journal of Labelled Compounds and Radiopharmaceuticals. 1999;42:653-661
[91] James O, Coleman RE: Radioiodinated MIBG in paraganglioma and pheochromocy-
toma: Previous results and early experiences using nocarrier-added MIBG. Nuclear 
Medicine and Biology. 2009;35:63-76
Radionuclide Treatments50
